Access Statistics for Paolo Pertile

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
A Bayesian Decision-Theoretic Model of Sequential Experimentation with Delayed Response 0 0 1 183 1 1 18 397
DRGs: the link between investment in technologies and appropriateness 0 0 0 27 3 3 17 140
Dynamic, economic approaches to HTA under uncertainty 0 0 0 45 1 1 4 176
Dynamic, incentive-compatible contracting for health services 0 0 0 11 0 0 12 25
Dynamic, incentive-compatible contracting for health services 1 1 2 9 4 7 22 37
Free-Riding in Pharmaceutical Price Regulation: Theory and Evidence 1 1 3 157 5 7 38 433
Late-Stage Pharmaceutical R & D and Pricing Policies under Two-Stage Regulation 0 0 1 59 3 3 12 168
L’ISEE in Italia: Una Nota Metodologica Partendo dai Dati IT-SILC 0 0 0 20 0 1 12 125
Modelling life-course decisions for the analysis of interpersonal and intrapersonal redistribution 0 0 0 18 3 4 21 177
Optimal sequential sampling rules for the economic evaluation of health technologies 0 0 0 86 2 2 12 263
Pricing policies when patients are heterogeneous: a welfare analysis 0 0 0 17 2 3 9 64
Public finance consolidation and fairness across living generations: the case of Italy 0 0 0 70 2 5 20 208
Public policies over the life cycle: a large scale OLG model for France, Italy and Sweden 0 0 1 65 3 4 12 117
R&D and market size: who benefits from orphan drug regulation? 0 0 0 76 2 4 15 213
Redistribution at the Local Level: The Case of Public Childcare in Italy 0 0 0 37 3 4 16 152
Spillovers of Pharmaceutical Price Regulations: evidence from the AMNOG Reform in Germany 0 0 5 29 0 3 30 100
Static and Dynamic Efficiency of Irreversible Health Care Investments under Alternative Payment Rules 0 0 0 40 2 3 7 137
The dynamics of pharmaceutical regulation and R&D investments 0 0 0 77 0 1 13 232
Who should monitor job sick leave? 0 0 0 28 0 1 8 124
Total Working Papers 2 2 13 1,054 36 57 298 3,288


Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
A Bayesian decision theoretic model of sequential experimentation with delayed response 0 0 0 3 0 0 8 39
A large scale OLG model for the analysis of the redistributive effects of policy reforms 0 0 0 43 1 1 29 164
A reply to “Who would benefit from average value‐based pricing?” 0 0 1 5 0 0 5 25
An extension of the real option approach to the evaluation of health care technologies: the case of positron emission tomography 0 0 0 16 2 2 6 92
Authors’ Reply to Garattini and Freemantle: “Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition” 0 0 0 3 2 2 9 37
Investment in Health Technologies in a Competitive Model with Real Options 0 0 0 34 1 1 13 123
Job sick leave: Detecting opportunistic behavior 0 1 1 9 0 1 14 51
Late-stage pharmaceutical R&D and pricing policies under two-stage regulation 0 0 0 9 2 2 10 72
Optimal Bayesian sequential sampling rules for the economic evaluation of health technologies 0 0 0 18 0 1 9 73
Optimal decision rules for HTA under uncertainty: a wider, dynamic perspective 0 0 0 17 0 0 8 74
R&D and market size: Who benefits from orphan drug legislation? 0 0 1 5 0 3 21 53
Redistribution at the local level: the case of public childcare in Italy 0 0 0 4 1 1 9 64
Static and dynamic efficiency of irreversible health care investments under alternative payment rules 0 0 1 22 0 0 13 161
Technology adoption, quality and health care costs: a review of the literature 0 0 0 4 1 1 14 45
The 2023 European Commission proposal and the 2024 European Parliament proposal for the EU pharmaceutical legislation: policy content analysis 0 1 4 4 1 2 16 16
The Dynamics of Pharmaceutical Regulation and R&D Investments 0 0 0 10 2 2 12 76
The Price of National Pharmaceutical Pricing in the EU: A Proposal for “Common Procurement” 0 0 0 0 0 0 0 0
The fiscal disadvantage of young Italians: a new view on consolidation and fairness 0 1 1 34 3 8 26 229
The impact of managed entry agreements on pharmaceutical prices 0 0 0 16 2 3 19 102
The timing of adoption of positron emission tomography: a real options approach 0 0 0 18 0 1 8 96
Two-part payments for the reimbursement of investments in health technologies 1 1 1 14 3 4 16 72
Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition 0 0 1 10 3 3 7 59
Which valued‐based price when patients are heterogeneous? 0 0 0 12 1 1 5 45
Total Journal Articles 1 4 11 310 25 39 277 1,768


Statistics updated 2026-11-12